Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immuno-Chemotherapy as Single Treatment Modality for Larynx Preservation (ICoLP)

NCT04030455 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT04030455
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04030455 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immuno-Chemotherapy as Single Treatment Modality for Larynx Preservation (ICoLP)
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 7, 2019
Completion date
September 17, 2026
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

laryngeal squamous cell carcinoma, stage ii laryngeal cancer ajcc v8, stage iii laryngeal cancer ajcc v8